X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 35.9 20.0 179.6% View Chart
P/BV x 9.2 3.5 264.1% View Chart
Dividend Yield % 0.7 0.3 248.8%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
GLENMARK PHARMA
Mar-18
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110930 657.0%   
Low Rs3,996517 772.3%   
Sales per share (Unadj.) Rs1,552.2322.6 481.2%  
Earnings per share (Unadj.) Rs188.828.5 662.7%  
Cash flow per share (Unadj.) Rs196.439.2 501.2%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.3 393.9%  
Book value per share (Unadj.) Rs796.6183.0 435.3%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.2 145.1%   
Avg P/E ratio x26.825.4 105.4%  
P/CF ratio (eoy) x25.718.5 139.3%  
Price / Book Value ratio x6.34.0 160.4%  
Dividend payout %29.17.0 414.9%   
Avg Mkt Cap Rs m107,376204,206 52.6%   
No. of employees `0003.313.7 24.2%   
Total wages/salary Rs m3,93718,718 21.0%   
Avg. sales/employee Rs Th9,929.36,636.8 149.6%   
Avg. wages/employee Rs Th1,185.11,364.7 86.8%   
Avg. net profit/employee Rs Th1,207.7586.1 206.1%   
INCOME DATA
Net Sales Rs m32,98591,031 36.2%  
Other income Rs m1,170914 128.0%   
Total revenues Rs m34,15591,945 37.1%   
Gross profit Rs m5,24516,154 32.5%  
Depreciation Rs m1623,019 5.4%   
Interest Rs m382,856 1.3%   
Profit before tax Rs m6,21511,193 55.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2033,155 69.8%   
Profit after tax Rs m4,0128,039 49.9%  
Gross profit margin %15.917.7 89.6%  
Effective tax rate %35.428.2 125.8%   
Net profit margin %12.28.8 137.7%  
BALANCE SHEET DATA
Current assets Rs m22,65569,887 32.4%   
Current liabilities Rs m6,68132,879 20.3%   
Net working cap to sales %48.440.7 119.1%  
Current ratio x3.42.1 159.5%  
Inventory Days Days6581 79.6%  
Debtors Days Days2993 31.2%  
Net fixed assets Rs m83528,892 2.9%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m16,71551,353 32.5%   
Net worth Rs m16,92851,635 32.8%   
Long term debt Rs m041,418 0.0%   
Total assets Rs m24,162125,954 19.2%  
Interest coverage x163.74.9 3,327.3%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x1.40.7 188.9%   
Return on assets %16.88.6 193.8%  
Return on equity %23.715.6 152.2%  
Return on capital %36.915.1 244.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36936,317 1.0%   
Fx outflow Rs m3,8079,720 39.2%   
Net fx Rs m-3,43826,598 -12.9%   
CASH FLOW
From Operations Rs m1,52716,481 9.3%  
From Investments Rs m-2,148-10,133 21.2%  
From Financial Activity Rs m-1,024-4,685 21.9%  
Net Cashflow Rs m-1,6461,770 -93.0%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 11, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - FDC LTD. COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS